Clinical Trial Update: Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a combination of sacituzumab govitecan and zimberelimab with SRS in metastatic triple-negative breast cancer with brain metastases; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING